Immuron Limited announced the submission of the Clinical Study Report for its Phase 2 clinical trial of Travelan® (IMM-124E) to the FDA, which demonstrated statistically significant immunological and ...
In its latest PFDD installment, the FDA offers a detailed roadmap for sponsors seeking to design, adapt, or validate COAs that accurately ...
Clinical Trials Arena on MSN
Pliant Therapeutics reports interim PLN-101095 phase I trial data
P liant Therapeutics has reported interim results from its ongoing Phase I dose escalation trial of PLN-101095, along with ...
View all available purchase options and get full access to this article. Supported by the National Health and Medical Research Council (NHMRC) Postgraduate Scholarship (APP2005294) to N.D.M, Emerging ...
TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative ...
Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a ...
As the curtain closed on 2024, FDA issued a new draft guidance to assist clinical trial sponsors, investigators, and institutional review boards (“IRBs”) with defining, identifying, and reporting ...
Clinical Trials Arena on MSN
UK patients being “denied access to cutting-edge clinical research”
The ABPI is calling on sites to set and meet higher recruitment targets, faster set-up, and executive accountability in NHS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback